idarubicin ( dmdr ) , a new analogue of daunorubicin , was administered orally once every 3 weeks at the dose of 40 to 45 mg/m2 to 20 evaluable patients with non-hodgkin 's lymphomas ( nhl ) .
C0020789
dmdr
C0011015
daunorubicin